• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Gastroenterology

Sofosbuvir therapy may be cost-effective for certain hepatitis C patients

byNicholas WoolfandSai Folmsbee
March 31, 2015
in Gastroenterology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. From a computer simulation, sofosbuvir-based regimens may be more cost-effective in patients with cirrhosis or previously treated with interferon.

Evidence Rating Level: 2 (Good)

Study Rundown: In 2013, the U.S. Food and Drug Administration (FDA) approved sofosbuvir, a nucleotide analog that inhibits viral RNA synthesis in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotypes 2 and 3. This novel drug can effectively induce a sustained virologic response (SVR) and has fewer side effects than pegylated interferon, which is the current standard of treatment. Sofosbuvir’s main drawback is its price; a four-week regimen currently costs about $28,000 in the U.S. This study used a Monte Carlo simulation and sensitivity analyses to determine the cost-effectiveness of sofosbuvir-based strategies for patients with HCV genotype 2 or 3. From this, it was determined that sofosbuvir-based therapy was cost-effective in patients with cirrhosis and in patients who had previously undergone interferon-based therapy. Conversely, sofosbuvir remains less cost-effective than interferon in non-cirrhotic, treatment-naïve patients. The study’s biggest limitation is that most HCV patients in the U.S. are infected with viral genotype 1 rather than 2 or 3, thereby narrowing its general application. Overall, this study suggests that the high cost of sofosbuvir may restrict its availability to many HCV patients infected with viral genotype 2 or 3.

Click to read the study, published today in the Annals of Internal Medicine

Relevant Reading: Sofosbuvir and ribavirin in HCV genotypes 2 and 3

In-Depth [simulation]: This study employed a Monte Carlo simulation to determine the cost-effectiveness of different treatment strategies for HCV genotype 2 or 3 infection. Patient data from published clinical trials and observational cohorts were used as part of this study. Patient types were defined by HCV genotype, treatment history, and cirrhosis status. Treatment strategies included pegylated interferon plus ribavirin, sofosbuvir plus ribavirin, and pegylated interferon, ribavirin and sofosbuvir. The simulation predicted clinical outcomes (represented by quality-adjusted life-years or QALYs) and costs (represented by the incremental cost-effectiveness ratio or ICER) for each patient type and treatment strategy. The results demonstrated that the pegylated interferon-ribavirin strategy was more cost-effective than sofosbuvir-ribavirin in non-cirrhotic HCV genotype 2 and 3 patients with no prior HCV treatment. In non-cirrhotic patients who had previously been treated with interferon, 12 weeks of sofosbuvir-ribavirin and 12 weeks of interferon-ribavirin-sofosbuvir were the most cost-effective strategies for genotype 2 and 3 patients, respectively. For cirrhotic patients, sofosbuvir-ribavirin was the most cost-effective strategy for genotype 2 and interferon-ribavirin-sofosbuvir was the most cost-effective strategy for genotype 3.

Image: PD

RELATED REPORTS

Accessible hepatitis C care for people who inject drugs provide significantly higher rates of cure compared to conventional care

Demographic trends associated with increased maternal & neonatal Hepatitis C cases over 10 years

Adenovirus encoding hepatitis C virus vaccine is safe but effectiveness is unclear

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: hepatitis Csofosbuvir
Previous Post

Exposure to air pollution linked to increased risk of stroke

Next Post

Intra-aortic balloon pumps do not improve mortality after severe acute myocardial infarctions

RelatedReports

Large spike in drug use-associated infective endocarditis linked with opioid epidemic
Gastroenterology

Accessible hepatitis C care for people who inject drugs provide significantly higher rates of cure compared to conventional care

March 17, 2022
Social networks play key roles in parental vaccination decisions
Chronic Disease

Demographic trends associated with increased maternal & neonatal Hepatitis C cases over 10 years

November 1, 2021
Compliance-linked incentives increase infant immunizations rates in rural India
Infectious Disease

Adenovirus encoding hepatitis C virus vaccine is safe but effectiveness is unclear

February 10, 2021
Screening insufficient for newborns exposed to hepatitis C virus
Cardiology

Expanding heart transplant in the era of direct-acting antiviral therapy for hepatitis C

December 28, 2019
Next Post
Reperfusion therapy may be suboptimal for STEMIs requiring transfers

Intra-aortic balloon pumps do not improve mortality after severe acute myocardial infarctions

Blood type correlates with egg reserve in infertile women

2 Minute Medicine Rewind March 23 – March 30, 2015

Mental retardation associated with IVF treatment

Elective egg freezing a cost-effective strategy to delay child bearing

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.